Second Young Adult Naturalistic Alcohol Study (YANAS-2)
This study involves completion of questionnaires, computer-based cognitive tasks and an alcohol drinking session. Participation in this study consists of an initial, in-person screening appointment, 4 brief daily appointments at the research office, an alcohol drinking session at a local bar and a follow-up appointment 1-3 days after the alcohol drinking session.
Participants who are found to be eligible in the screening phase will then complete a daily appointment for 4 days out of a 5-day period (i.e., there will be 1 day out of the 5 on which they will not attend an appointment). Each appointment will last 20 minutes, on average and consist of a questionnaire and computer-based cognitive task. On the day of the fourth appointment, participants will complete an alcohol drinking session. The alcohol drinking session begins at 4pm and lasts until at least midnight.
Participants in this study will be young adults between the ages of 21-25, who regularly drink alcohol and are not currently seeking treatment for alcohol use. Seventy-two participants will complete this study.
|Young Adult Alcohol Drinking|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Second Young Adult Naturalistic Alcohol Study (YANAS-2)|
- Peak estimated blood alcohol concentration [ Time Frame: During a 3-hour alcohol drinking period ]
- Number of alcoholic drinks consumed [ Time Frame: During a 3-hour alcohol drinking period ]
- Self-reported drinks per drinking day [ Time Frame: 6- and 12-month follow-ups after alcohol drinking session ]
- Self-reported frequency of heavy drinking days [ Time Frame: 6- and 12-month follow-up after alcohol drinking session ]
|Study Start Date:||January 2013|
|Study Completion Date:||October 2016|
|Primary Completion Date:||November 2015 (Final data collection date for primary outcome measure)|
Young adult alcohol drinkers
Young adults between the ages of 21-25 who regularly drink alcohol
Please refer to this study by its ClinicalTrials.gov identifier: NCT01780805
|United States, Connecticut|
|Yale University School of Medicine|
|New Haven, Connecticut, United States, 06519|
|Principal Investigator:||Robert F Leeman, Ph.D.||Yale University|